ICOTYDE icotrokinra Updated Nov 9
ICOTYDE is already approved and generating revenue. The next major catalyst would be a regulatory filing for psoriatic arthritis (Phase 3 data just presented at ACR Nov 2026), but no submission or PDUFA date has been announced yet. Watch for J&J's filing plans and quarterly royalty revenue growth as the commercial launch ramps.
- ICOTYDE is the first and only FDA-approved oral peptide targeting IL-23R for plaque psoriasis, offering a novel once-daily pill alternative to injectable biologics in a multi-billion-dollar market.
- BofA sees peak sales potential of $4.5 billion for ICOTYDE, suggesting substantial royalty revenue upside for Protagonist if J&J executes on the commercial launch.
- Phase 3 psoriatic arthritis data (presented Nov 2026 at ACR) showed 58% ACR20 vs 41% placebo, opening a large label-expansion opportunity that could significantly increase the addressable market.
- Insider selling: CFO Ali Asif sold $6.5M+ in stock on Sept 30, 2026, and CEO Dinesh Patel sold over $20M in stock across multiple transactions in Aug-Sep 2026 (all under 10b5-1 plans but still notable).
- Several large institutional holders exited or trimmed positions in Q2 2026, including Citadel (exit), Adage Capital (exit), Rubric Capital (exit), and Marshall Wace (near-exit), suggesting profit-taking after the approval-driven rally.
- Competition in the oral psoriasis market is intensifying: Sotyktu (deucravacitinib, BMS) is already on the market, and Alumis is advancing envudeucitinib (TYK2 inhibitor) through Phase 3 with positive data.